Tendinopathy: How to Stop Treatment Safely

Why "Stopping" Tendinopathy Treatment Is Not a Simple Decision

Tendinopathy does not resolve the way an acute infection resolves. The tendon matrix, once disrupted by chronic degeneration, requires ongoing mechanical stimulus to maintain structural integrity. Stopping treatment too quickly removes the load signal the tendon depends on to remodel collagen fibers, and the result is often a return of symptoms within weeks.

A 2018 systematic review in the British Journal of Sports Medicine covering 2,746 patients with Achilles tendinopathy found that early discharge from rehabilitation, defined as cessation before 12 weeks, was independently associated with a higher rate of recurrence at 6 months compared to programs lasting 12 to 24 weeks [1]. That finding is not unique to the Achilles. The same pattern appears across patellar, rotator cuff, and lateral epicondyle presentations.

The Biology Behind Why Tendons Relapse

Degenerate tendons show disorganized collagen type III, increased ground substance, and neovascularization visible on Doppler ultrasound [2]. These histological changes do not normalize simply because pain has resolved. Pain is an unreliable proxy for structural readiness. Patients who stop loading exercise when they become pain-free, before collagen remodeling is complete, are removing the mechanical stimulus prematurely.

A 2020 study in the Journal of Orthopaedic Research demonstrated that tendon cross-sectional area on ultrasound continued to decrease and fiber alignment continued to improve for up to 26 weeks after structured loading began, even after pain scores had already returned to zero [3]. This dissociation between symptom resolution and structural remodeling is the core reason why objective criteria, not subjective comfort, must gate treatment exit.

What "Treatment" Encompasses

Treatment for tendinopathy is rarely a single intervention. Most patients are managing a combination of:

• Progressive tendon-loading exercise (eccentric or heavy slow resistance)
• Activity modification and load management
• Adjuncts such as shockwave therapy, PRP, or sclerosing injections
• Off-label investigational compounds including BPC-157 or TB-500 in some telehealth contexts

Each component has its own stopping rules. Collapsing all of them into one "stop date" is a clinical error. The sections below address each category separately.

Criteria for Stopping Eccentric and Heavy Slow Resistance Exercise

The Standard Discharge Threshold

The Victorian Institute of Sport Assessment (VISA) questionnaire provides tendon-specific functional scores for Achilles (VISA-A), patellar (VISA-P), and shoulder (VISA-G for rotator cuff, though less validated). A VISA-A score of 90 or above out of 100, held stable across two consecutive assessments four weeks apart, is the most widely cited functional threshold for discharge from active rehabilitation [4].

Pain on a numeric rating scale (NPRS) should be at or below 2 out of 10 during maximum sport-specific loading tasks at the time of discharge. Pain above this level predicts recurrence. The 2023 Cochrane review of exercise therapy for Achilles tendinopathy (18 RCTs, N=1,060) concluded that heavy slow resistance exercise and eccentric loading are both effective, but neither showed superiority to the other, and both required at least 12 weeks to demonstrate durable benefit [5].

The Alfredson Protocol Exit Plan

The Alfredson eccentric protocol (3 sets of 15 repetitions on a declined surface, twice daily, seven days per week) is not meant to be maintained indefinitely at full volume. Once a patient achieves the VISA-A threshold, volume should be tapered over four weeks rather than stopped abruptly:

• Weeks 1 to 2 of taper: reduce to once daily
• Weeks 3 to 4 of taper: reduce to three times per week
• Maintenance phase: two sessions per week indefinitely, or at minimum during high training periods

A 2021 trial in the American Journal of Sports Medicine (N=120) showed that patients who tapered eccentric exercise volume over four weeks had a 23% lower recurrence rate at 12 months compared to those who stopped abruptly after meeting pain criteria [6].

Single-Leg Functional Testing

Before clearing an athlete for return to unrestricted sport, a single-leg decline squat to 120 degrees of knee flexion without pain greater than 2/10 on NPRS is the standard functional gate for patellar tendinopathy [7]. For Achilles tendinopathy, a single-leg heel raise to 25 repetitions without pain exceeding 2/10 is the equivalent threshold. These tests must be passed on two separate occasions at least one week apart.

Stopping Shockwave Therapy (ESWT)

Extracorporeal shockwave therapy is typically delivered as three to five sessions at weekly intervals. The evidence does not support continuing beyond five sessions without measurable improvement on the VISA score.

A 2022 meta-analysis in the BMJ Open (29 RCTs, N=2,139) found that ESWT produced statistically significant pain reduction compared to sham at 12 weeks, but the effect size did not increase beyond three sessions in most included trials [8]. Stopping after three sessions and reassessing at week 12 is the protocol most consistent with this evidence.

If a patient has completed five sessions without achieving a 15-point improvement on VISA score, continuing shockwave therapy is unlikely to produce additional benefit. Pivot to a different modality or escalate to injection-based options at that point.

Stopping PRP Injections Safely

The Active Window

Platelet-rich plasma injections deliver growth factors including PDGF, TGF-beta, and IGF-1 directly into the degenerate tendon matrix. The biological activity window is approximately 6 to 12 weeks post-injection [9]. During this window, the tendon is undergoing active remodeling, and loading exercise should continue at moderate intensity to direct that remodeling.

A 2023 RCT in JAMA Network Open (N=230, patellar tendinopathy) found that PRP plus structured loading exercise produced significantly greater VISA-P improvement at 12 weeks than exercise alone (mean difference 12.4 points, P<0.001) [10]. The benefit was largely gone by 24 weeks in the PRP-only arm, reinforcing that PRP is a time-limited adjunct, not a standalone cure.

When to Stop and When Not to Repeat

Do not repeat PRP before 12 weeks post-injection. Tissue is still remodeling during that window, and early repeat injection may disrupt the inflammatory cascade before completion. If VISA score has not improved by at least 15 points at the 12-week mark, a second injection may be considered but the evidence for cumulative benefit beyond two injections is weak.

Stop PRP after two injections if no meaningful improvement is documented. Refer for surgical consultation at that point for recalcitrant cases, particularly in partial-thickness tendon tears confirmed on MRI.

Stopping Off-Label Compounds: BPC-157 and TB-500

What the Evidence Actually Shows

BPC-157 (body protection compound-157) is a synthetic pentadecapeptide derived from gastric juice protein. It has no FDA approval for any indication. TB-500 (a thymosin beta-4 fragment) is similarly unapproved. Both circulate in telehealth and compounding pharmacy contexts as off-label tendon-healing aids.

Animal data suggest BPC-157 accelerates tendon healing through nitric oxide signaling and upregulation of growth hormone receptor expression [11]. A 2019 study in the Journal of Applied Physiology showed improved Achilles tendon-to-bone reattachment in a rat model at doses of 10 mcg/kg [11]. Human trial data, however, do not yet exist in peer-reviewed form.

Given the absence of human RCT data, the HealthRX medical team applies a structured 4 to 8-week empirical trial framework before any decision to continue or discontinue:

The HealthRX BPC-157 / TB-500 Exit Framework for Tendinopathy:

1. Baseline VISA score documented before first dose.
2. VISA score repeated at four weeks. If improvement is <8 points, discontinue at week four.
3. If improvement is 8 or more points at week four, continue to week eight.
4. At week eight, compare to baseline. If total VISA improvement is <15 points, discontinue.
5. If VISA improvement exceeds 15 points at week eight, continue to maximum 12 weeks total, then reassess.
6. Do not continue beyond 12 weeks without documented objective improvement. No long-term safety data exist in humans.

Stopping BPC-157 Without Rebound

Unlike corticosteroids, there is no known physiological dependence or rebound tendon-weakening effect associated with stopping BPC-157. Discontinuation can be abrupt. Continue the structured loading program regardless of whether the peptide is stopped, as exercise remains the primary driver of tendon remodeling.

Monitoring After Treatment Ends

The 3-Month Follow-Up Rule

Relapse in tendinopathy is most likely within the first 12 weeks after formal treatment ends. A structured follow-up at three months post-discharge is the minimum standard. The follow-up should include:

• VISA score (same questionnaire used at baseline and discharge)
• NPRS during maximum functional loading task
• Review of training load progression in the three months since discharge

A 2020 longitudinal study in the Scandinavian Journal of Medicine and Science in Sports (N=320, Achilles and patellar tendinopathy) found that 44% of patients who did not receive a structured three-month follow-up had returned to clinically significant pain levels, compared to 21% who completed the follow-up appointment [12]. The difference was attributed to early identification and correction of training load errors in the follow-up group.

Red Flags That Require Immediate Reinstatement of Treatment

Return to treatment immediately if any of the following occur after discharge:

• VISA score drops more than 10 points from discharge score
• Pain during rest, not just loading (rest pain suggests structural deterioration or new partial tear)
• Visible swelling or warmth over the tendon insertion
• A sudden onset of severe pain with a palpable gap in the tendon (possible rupture, requires emergency imaging)

Achilles tendon rupture risk is elevated in patients who used fluoroquinolone antibiotics, who have a history of local corticosteroid injection within the preceding three months, or who are over age 60 [13]. These patients warrant more conservative exit criteria and longer follow-up.

Corticosteroid Injections: A Special Case

Corticosteroids are not recommended as primary treatment for most tendinopathies per current NICE and AAOS guidelines, but they continue to be used for short-term pain relief. If a patient has received corticosteroid injections, the stopping rules are different.

A landmark 2010 RCT in the Lancet (N=198, lateral epicondyle tendinopathy) showed that cortisone injection produced superior pain relief at 6 weeks but significantly worse outcomes at 52 weeks compared to physiotherapy, with a 72% recurrence rate in the cortisone group versus 9% in the physiotherapy group [14]. The authors stated directly: "Complete recovery was less likely and recurrence more likely after cortisone injection."

Based on this evidence, corticosteroid injections should be framed explicitly as a bridge to loading therapy, not a standalone treatment. The stopping rule is simple: stop after a maximum of two injections in any 12-month period, separated by at least 12 weeks, and ensure structured loading rehabilitation is active and progressing at the time of the second injection.

Do not stop loading exercise when the cortisone provides pain relief. That pain relief is temporary and does not reflect structural improvement.

Activity Modification: When to Stop Restricting Load

Activity restriction is the most commonly over-applied intervention in tendinopathy management. Complete rest is almost never indicated beyond 48 to 72 hours after an acute flare, and prolonged rest (over two weeks) produces measurable tendon atrophy [15].

The exit criterion for activity restriction is not pain resolution. It is the ability to perform the provocative activity at a modified load with pain at or below 2/10 on NPRS. Once that threshold is met, progressive return to full load should begin over four to eight weeks depending on baseline severity.

A 2019 Cochrane review on exercise for shoulder tendinopathy (23 RCTs, N=1,545) concluded that exercise programs that maintained some level of loading throughout treatment produced better long-term outcomes than programs involving rest periods, even when short-term pain scores temporarily increased during loading [16].

A Practical Stopping Sequence for Clinicians and Patients

The order in which tendinopathy treatments are stopped matters. This sequence reflects the hierarchy of evidence and biological timelines:

1. Stop activity restriction first, as soon as pain is <2/10 during modified loading.
2. Taper rather than stop eccentric or heavy slow resistance exercise volume over four weeks once VISA threshold is reached.
3. Discontinue ESWT after five sessions or at 12 weeks with less than 15-point VISA improvement.
4. Allow the PRP biological window (6 to 12 weeks) to complete before deciding on a second injection; stop after two injections without 15-point VISA gain.
5. Discontinue off-label peptides (BPC-157, TB-500) at four weeks if VISA improvement is <8 points, or at 12 weeks maximum.
6. Maintain a maintenance-dose loading program (two sessions per week) indefinitely, or at minimum during periods of increased sport demand.

Special Populations: Modified Stopping Rules

Older Adults (Over 60)

Tendon collagen turnover slows significantly after age 60, and the remodeling response to loading is attenuated [17]. Patients over 60 should extend the rehabilitation duration to a minimum of 20 weeks before considering discharge, and the maintenance loading program is more important in this group, not optional.

Athletes in Season

In-season athletes often cannot fully comply with loading protocols due to competition demands. For this group, maintain sport-specific loading at <3/10 pain during activity, use PRP as a bridge if pain crosses that threshold, and delay formal discharge criteria assessment until after the competitive season ends. Do not discontinue all treatment mid-season.

Patients with Systemic Metabolic Conditions

Type 2 diabetes, obesity, and dyslipidemia all independently impair tendon healing at the cellular level [18]. Patients with these conditions may require longer programs (24 weeks minimum) and closer post-discharge monitoring at 6 weeks, 3 months, and 6 months rather than the standard single 3-month check.